These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21708208)

  • 1. The development of Dengue vaccines. Introduction.
    Coller BA; Barrett AD; Thomas SJ
    Vaccine; 2011 Sep; 29(42):7219-20. PubMed ID: 21708208
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of dengue DNA vaccines.
    Danko JR; Beckett CG; Porter KR
    Vaccine; 2011 Sep; 29(42):7261-6. PubMed ID: 21777640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical development of a dengue recombinant subunit vaccine.
    Manoff SB; George SL; Bett AJ; Yelmene ML; Dhanasekaran G; Eggemeyer L; Sausser ML; Dubey SA; Casimiro DR; Clements DE; Martyak T; Pai V; Parks DE; Coller BA
    Vaccine; 2015 Dec; 33(50):7126-34. PubMed ID: 26458804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation dengue vaccines: a review of candidates in preclinical development.
    Schmitz J; Roehrig J; Barrett A; Hombach J
    Vaccine; 2011 Sep; 29(42):7276-84. PubMed ID: 21781998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic acid (DNA) immunization as a platform for dengue vaccine development.
    Porter KR; Raviprakash K
    Vaccine; 2015 Dec; 33(50):7135-40. PubMed ID: 26458805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows.
    Normile D
    Science; 2007 Sep; 317(5844):1494-5. PubMed ID: 17872423
    [No Abstract]   [Full Text] [Related]  

  • 8. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
    Coller BA; Clements DE; Bett AJ; Sagar SL; Ter Meulen JH
    Vaccine; 2011 Sep; 29(42):7267-75. PubMed ID: 21777637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
    Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
    Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
    Lam SK
    Expert Rev Vaccines; 2013 Sep; 12(9):995-1010. PubMed ID: 24053394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A normal life in science.
    Coller BA
    Hum Vaccin; 2010 Jul; 6(7):528-31. PubMed ID: 20622512
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in dengue vaccine development.
    Raviprakash K; Defang G; Burgess T; Porter K
    Hum Vaccin; 2009 Aug; 5(8):520-8. PubMed ID: 19535912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the clinical development of a dengue vaccine.
    Wallace D; Canouet V; Garbes P; Wartel TA
    Curr Opin Virol; 2013 Jun; 3(3):352-6. PubMed ID: 23747120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue vaccine: an update on recombinant subunit strategies.
    Martin J; Hermida L
    Acta Virol; 2016 Mar; 60(1):3-14. PubMed ID: 26982462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction.
    Coller BA; Barrett AD; Thomas SJ
    Vaccine; 2015 Dec; 33(50):7049-50. PubMed ID: 26597033
    [No Abstract]   [Full Text] [Related]  

  • 17. Dengue vaccines: progress and challenges.
    Coller BA; Clements DE
    Curr Opin Immunol; 2011 Jun; 23(3):391-8. PubMed ID: 21514129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant bacterial lipoproteins as vaccine candidates.
    Leng CH; Liu SJ; Chen HW; Chong P
    Expert Rev Vaccines; 2015; 14(12):1623-32. PubMed ID: 26420467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domain III of the envelope protein as a dengue vaccine target.
    Guzman MG; Hermida L; Bernardo L; Ramirez R; Guillén G
    Expert Rev Vaccines; 2010 Feb; 9(2):137-47. PubMed ID: 20109025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.